Skip to content

Comparison of remimazolam versus remimazolam in combination with low-dose esketamine in the relief of dental anxiety in patients with dental anxiety disorders undergoing oral therapy

Comparison of remimazolam versus remimazolam in combination with low-dose esketamine in the relief of dental anxiety in patients with dental anxiety disorders undergoing oral therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104876
Enrollment
Unknown
Registered
2025-06-25
Start date
2025-06-30
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dental anxiety

Interventions

R Group:Intravenous injection of the corresponding dose of normal saline (injection time 5min), remimazolam 0.08mg/kg (injection time 5min)
RE Group:Intravenous esketamine 0.2mg/kg (injection time 5 min), remimazolam 0.08 mg/kg (injection time 5 min)

Sponsors

The Eighth Affiliated Hospital , Southern Medical University (The First People's Hospital of Shunde District, Foshan City)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1.Modified Dental Anxiety Scale (MDAS) score >= 12 points; 2.patients undergoing outpatient oral treatment; 3.Age (18~65y); 4.Body mass index: 18.5~30 kg.m^2; 5.ASA Grading I-II;

Exclusion criteria

Exclusion criteria: 1.Patients with a history of heavy alcohol consumption or alcohol or drug dependence; 2. patients who regularly use benzodiazepines; 3.Patients with contraindications to benzodiazepines or esketamine; 4.Patients with severe mental illness; 5.Patients with severe cardiovascular, pulmonary, hepatic and renal dysfunction or impaired adrenal cortical function; 6.pregnant patients; 7.Patients with structural brain diseases; 8.Patients who refuse to participate or those who are not suitable to participate in this trial; 9.Patients with obstructive sleep apnea-hypopnea syndrome or respiratory tract difficulties.

Design outcomes

Primary

MeasureTime frame
Modified Dental Anxiety Scale score within 2 hours after surgery;

Secondary

MeasureTime frame
Preoperative Modified Dental Anxiety Scale score;Visual Analogue Scale for Anxiety (VAS-A);Pain Behavior Scale (BPS);time to onset of sedation ;Satisfaction of the dentist and evaluation of the patient's mouth opening (1. Very satisfied; 2. Satisfied; 3. Neutral; 4. Dissatisfied; 5. Very dissatisfied. ), patient satisfaction, and patient memory of the treatment process;Unintentional movement: gag reflex, coughing, or excessive movement, etc;EEG bispectral index, BIS ;Total remimazolam dosage;Modified Dental Anxiety Scale score response rate;Modified Dental Anxiety Scale score remission rate;success rate of sedation;The dentist evaluates the patient's mouth opening;Patient satisfaction;Patient's memory of the treatment process;Vital signs;

Countries

China

Contacts

Public ContactZhang Yiwen

The Eighth Affiliated Hospital of Southern Medical University

ssss047@163.com+86 137 9464 7543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026